At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Doxycycline +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Doxycycline, Management of Therapy Complications, and 5 other interventions for Advanced Malignant Neoplasm and Dermatologic Complication. Completed, enrolled 19 participants across 5 sites.
Detailed Summary
This randomized phase II trial studies how well giving spironolactone works in preventing rash in patients with cancer that has spread to other places in the body and are receiving panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin rash.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedJun 2013
Primary CompletionMay 2014
Study CompletionJun 2014
TodayJul 2026
First PostedJun 4, 2013
Enrollment StartAug 31, 2012
Primary CompletionMay 9, 2014
Study CompletionJun 13, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.1 years ago
Interventions
Doxycyclinedrug
Given PO
Management of Therapy Complicationsprocedure
Moisturizer given topically
Placeboother
Given topically
Questionnaire Administrationother
Ancillary studies
Spironolactonedrug
Given topically
Sunscreendrug
Given topically
Therapeutic Hydrocortisonedrug
Given topically